Status:
UNKNOWN
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Chronic Hepatitis C Infection
HCV Genotype 1b
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Chronic Hepatitis C Virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma world-wide. Current combination therapy of pegylated interferon-alfa, ribavirin and protease ...
Eligibility Criteria
Inclusion
- Chronic genotype 1b hepatitis C infection with detectable HCV RNA (\> 1x104 UI/mL)
- Naïve, relapser or non-responder to interferon with or without ribavirin
- Weight \> 45kg, BMI between 18 and 25 Kg/m2 who had a liver biopsy or liver FibroScan eliminating the presence of cirrhosis in the year before enrollment,
- Non-smoker or occasional smoker ( ie \< 3 cig/day)
Exclusion
- HIV or HBV infection
- Cirrhosis or Liver decompensation
- Chronic liver disease non related to HCV
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2015
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01835938
Start Date
May 1 2013
End Date
May 1 2015
Last Update
June 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Hépatogastroentérologie, NHC1, place de l'hôpital
Strasbourg, Alsace, France, BP n°426